Comparison of the efficacy of Tacrolimus 0.1% ointment and Tacrolimus 0.1% plus topical pseudocatalase/superoxide dismutase gel in children with limited vitiligo: a randomized controlled trial

Alshiyab, Diala; Al‐Qarqaz, Firas; Muhaidat, Jihan; Khader, Yousef; Al-sheyab, Ruba F.; Jafaar, Sala I.

doi:10.1080/09546634.2020.1729952

Cited by 11 publications

(18 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No added benefit was observed with the combination therapy (45). A study performed by Alshiyab et al (46), comparing the efficacy of tacrolimus 0.1% ointment to tacrolimus 0.1% ointment plus topical pseudocatalase/superoxide dismutase gel in the treatment of children with localized vitiligo, demonstrated that there was no significant difference in repigmentation percentages between the two groups. However, information on side effects and safety of pseudocatalase is lacking (47).…”

Section: Topical Treatmentmentioning

confidence: 99%

Updates and new medical treatments for vitiligo (Review)

et al. 2021

View full text Add to dashboard Cite

Vitiligo is a multifactorial disease characterized by the loss of skin pigment, which results in achromic macules and patches. There are currently several medical treatments available, which aim to arrest progression and induce skin repigmentation. These treatments alone or combined have exhibited varying degrees of pigmentation, and the majority are safe and effective. All therapies for vitiligo are limited, and no known treatment can consistently produce repigmentation in all patients. Individualized treatment is appropriate according to the location, clinical presentation and the presence of disease activity. The present review summarizes the medical treatments available for vitiligo: Systemic and topic pharmacological therapies, physical and depigmentation treatments. Several treatments are still underway and have not yet been approved. However, due to the promising preliminary results, these are also mentioned in the present review. Contents 1. Introduction 2. Pharmacological treatment 3. Physical therapy 4. Depigmentation therapies 5. Conclusions

show abstract

Section: Topical Treatmentmentioning

confidence: 99%

Updates and new medical treatments for vitiligo (Review)

et al. 2021

View full text Add to dashboard Cite

show abstract

“…8 However, the number of RCTs testing tacrolimus monotherapy in vitiligo remains inadequate. [10][11][12][13][14][15][16][17][18][19] Previous RCTs addressing topical tacrolimus monotherapy in vitiligo included patients from different continents namely:…”

Section: Discussionmentioning

confidence: 99%

“…Previous RCTs recorded wide range of repigmentation rates following tacrolimus monotherapy in vitiligo (6.8%, 18 50%, 15 58%, 11 60%, 19 69.6%, 17 75.8%, 16 83%, 14 and 90%) 10 . Such variation in repigmenation rates may be due to differences in tacrolimus concentration, duration of therapy, patients’ age, type and anatomical site of vitiligo, and differences in the definition of repigmenation.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of topical tacrolimus 0.03% monotherapy in the treatment of non‐segmental vitiligo: a randomized, controlled trial

Saleh

Ahmed²,

Abd-Elmagid

2021

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Several hypotheses have been suggested for the pathogenesis of vitiligo including biochemical, neural, and autoimmune theories. 1 Topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are frequently used as first-line treatment of vitiligo based on their immnuesuppressive and immunemodulatory actions. 2 Despite excellent repigmenation rates provided by TCSs, their long-term use is often complicated with skin atrophy, striae, and telangiectasia. 3 Topical calcineurin inhibitors have been considered as alternatives to TCSs for vitiligo therapy given their reasonable efficacy and better short-term safety. 4 Tacrolimus is a member of the TCIs' family that acts through inhibition of T-helper (Th) cells, thus reducing synthesis and release of pro-inflammatory cytokines. 5 Cytokine transcription blockage leads to decrease in Th 1 -and Th 2 -dependent release of interleukins 2, 3, 4, and 5, interferonγ, and tumor necrosis factorα. 6 Oral tacrolimus has been approved by the Food and Drug Administration (FDA) for prophylaxis against rejection in kidney and liver transplant

show abstract

“…Topic catalase for repigmentation in vitiligo reduces H 2 O 2 and may prevent oxidative damage (91). Alshiyab et al (91) reported that the combination of topical pseudocatalase/dismutase gel and 0.1% tacrolimus ointment did not have markedly different results compared with 0.1% tacrolimus ointment monotherapy in children with <10% of body surface area affected by vitiligo. However, clinical trials concerning antioxidants in the treatment of vitiligo are limited by the number of patients and studies with larger study populations are warranted.…”

Section: Immunopathogenesis Of Vitiligomentioning

confidence: 99%

Novel immunological and genetic factors associated with vitiligo: A review

et al. 2021

View full text Add to dashboard Cite

Vitiligo is a skin disorder characterized by depigmentation of the skin due to a lack of melanin. This condition affects men and woman of all ages and its incidence is not restricted by ethnicity or region. Vitiligo is a multifactorial disease, in which melanocytes, which serve important functions in skin pigmentation and immune processes, are impaired. There is sufficient evidence that immunological and genetic factors are primarily responsible for the destruction and dysfunction of melanocytes. Therefore, genetic DNA sequence variants that participate in skin homeostasis, pigmentation and immune response regulation, as well as altered expression patterns, may contribute to the risk of developing vitiligo. The current review presented an overview of the mechanism of pigmentation and of currently known factors involved in depigmentation, as well as the classification, epidemiology, associated comorbidities, risk factors, immunopathogenesis and several genetic and molecular changes associated with vitiligo. Contents 1. Overview 2. Immunopathogenesis of vitiligo 3. Genetic factors associated with vitiligo 4. Conclusions

show abstract

Comparison of the efficacy of Tacrolimus 0.1% ointment and Tacrolimus 0.1% plus topical pseudocatalase/superoxide dismutase gel in children with limited vitiligo: a randomized controlled trial

Cited by 11 publications

References 14 publications

Updates and new medical treatments for vitiligo (Review)

Updates and new medical treatments for vitiligo (Review)

Efficacy of topical tacrolimus 0.03% monotherapy in the treatment of non‐segmental vitiligo: a randomized, controlled trial

Novel immunological and genetic factors associated with vitiligo: A review

Contact Info

Product

Resources

About